|

A Doctor Explains Ibogaine: A Psychedelic Plant Being Used to Heal Addictions

BySarah Abelsohn



A Doctor Explains Ibogaine: A Psychedelic Being Used to Heal Addictions

Interested in becoming a psychedelic therapist? Enroll in Dr. Erica Zefland’s course, the Science of Psychedelics: https://scienceofpsychedelics.com/?ref=PSYCspotlight

The Science of Psychedelics is an accredited, definitive guide to the clinical applications of entheogenic medicines, and offers a solid introduction to psychedelic-assisted therapy and “trip sitting’ skills to physicians, psychologists, social workers, mental health counselors, pharmacists, and other empowered individuals.

Use the link above, or coupon code “PSYCspotlight”, for 15% off.

In today’s episode, we talk with Dr. Erica Zelfand, a medical doctor and holistic practitioner with experience in administering ibogaine. Psychedelic Therapy is making waves in the mental health spaces, and ibogaine is one of the psychedelics with the most potential.

Follow us on Twitter: @PsycSpotlight
Follow us on Instagram: @psycspotlight
Like us on Facebook: https://www.facebook.com/PsychedelicSpotlight

To learn more about the emerging psychedelics industry, visit:

Psychedelic Spotlight

In this episode, we learn what ibogaine is, how it is used, and how natural and synthetic ibogaine differ. We also learn how ibogaine can help with addiction, even though it is currently illegal in the United States. Finally, we learn how ibogaine interacts with brain chemistry.

Dr. Zelfand traveled to Mexico, where ibogaine is legal, to observe retreats where people used the substance to help treat depression, addiction, and more. Specifically, ibogaine appears to be useful for treating Opioid Use Disorder.

It is important to know that ibogaine does carry with it some health risks. Individuals need to make sure they have healthy liver and heart functions before engaging in its use.

We do not condone the use of ibogaine without the assistance of a licensed professional.

#Psychedelic #MentalHealth #Ibogaine

source

Similar Posts

  • Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]

    Listen, Videos

    Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).

    In this video, we’ll cover:
    1. Compass Pathways’ Financials
    2. Their IP
    3. Therapists Training
    4. Future Projects
    5. Digital Technology

    I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
    https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #CompassPathways #CMPS #MindMed

  • Interview With Laura Dawn

    Listen, Podcasts

    In today’s episode of the Psychedelic Spotlight podcast, we feature Laura Dawn- a microdosing mentor, visionary life coach, business consultant, author, international speaker, and host of the Psychedelic Leadership podcast.

  • Interview with Joseph Mays, IRI Program Director at Chacruna

    Listen, Podcasts

    In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.

  • Psychedelics Aiding Recovery with Arrowyn Ambrose

    Listen, Podcasts

    In this episode, Arrowyn speaks on how psychedelics are integrated into recovery and addiction, how community can profoundly impact those in recovery, and how we can assist those who are in need of psychedelic therapy but may not have access.

  • How Long Until Psychedelic Stocks Payoff?🍄🚀| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more

    Listen, Videos

    How long until Psychedelic Stocks Payoff?🍄🚀

    To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.

    And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.

    In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”

    Or, translated to Reddit-speak: when moon?

    To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.

    There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.

    The first will happen relatively soon.

    #PsychedelicStocks #MindMed #Cybin